 pilot studi low-dos zidovudin human immunodefici viru infect background zidovudin progress human immunodefici viru hiv infect hematolog toxic high dose regimen preserv enhanc efficaci toxic acyclovir effect zidovudin hiv vitro method phase II open-label dose-escal trial clinic antivir effect zidovudin low mg subject medium mg subject high mg subject acyclovir random assign subject immunodefici syndrom aid complex aid hiv antigenemia plasma viremia count cubic millimet treatment result perform score fatigu low- medium-dos zidovudin group equal low-dos zidovudin weight improv mean count cubic millimet base line cubic millimet week proport subject hiv antigenemia decreas level antigenemia reduct plasma viru titer similar dose subject low medium dose dose increas count declin level hiv antigen dose-rel toxic addit acyclovir zidovudin zidovudin antiretrovir effect conclus pilot low dose zidovudin mg clinic virolog effect similar daili dose mg minim effect dose zidovudin treatment hiv infect studi low daili dose